Cancer Screening and Prevention

Cancer screening and prevention covers the strategies used to reduce cancer incidence and mortality through primary prevention (reducing exposure to risk factors), secondary prevention (early detection by screening), and the systematic organization of screening programs. It draws on the long-established principles that govern when screening for a disease is justified and effective.

Definition

Cancer screening and prevention is the set of population- and individual-level activities that aim to reduce the occurrence and mortality of cancer by lowering exposure to risk factors and by detecting cancer or its precursors early through screening.

Scope

This topic describes how cancer prevention is structured in community and public health nursing: the levels of prevention, the criteria that determine whether a screening program is appropriate, and the population logic of early detection. It is a reference entry on the structure and principles of prevention and screening, not a source of individual screening schedules or clinical recommendations.

Core questions

• What distinguishes primary cancer prevention from screening-based secondary prevention?
• Under what conditions is screening for a cancer justified?
• Why can screening cause harm as well as benefit?
• How is the global burden of cancer distributed?

Key concepts

• Primary prevention (risk-factor reduction)
• Secondary prevention (screening and early detection)
• Wilson and Jungner screening criteria
• Sensitivity, specificity, and predictive value
• Overdiagnosis and false positives
• Organized versus opportunistic screening
• Lead-time and length-time bias

Mechanisms

Cancer prevention operates on two complementary fronts. Primary prevention reduces the incidence of cancer by lowering exposure to causal and risk factors such as tobacco, certain infections, and other carcinogens. Secondary prevention, or screening, seeks to detect cancer or pre-cancerous changes at an early, more treatable stage in people without symptoms. Whether screening is worthwhile is governed by long-standing criteria articulated by Wilson and Jungner: the condition should be an important health problem with a recognizable early stage, there must be a suitable and acceptable test, an effective treatment must exist, and the benefits must outweigh the harms. Because no test is perfect, screening generates false positives and can lead to overdiagnosis, so program design must weigh detection benefits against these harms and against biases such as lead-time and length-time bias that can make screening appear more beneficial than it is.

Clinical relevance

Cancer is a leading cause of death worldwide, and nurses contribute to prevention counselling, screening promotion, and the organization and delivery of screening programs. This entry explains the principles and trade-offs of cancer prevention and screening at the program level; it is educational reference material and does not set individual screening intervals or clinical recommendations.

Epidemiology

Cancer is among the leading causes of death globally, with the GLOBOCAN 2022 estimates documenting many millions of new cases and deaths each year across dozens of cancer types and a marked burden gradient between higher- and lower-resource settings. This burden underpins both primary prevention and organized screening as public health priorities.

History

The conceptual foundation of disease screening was set out in 1968 by Wilson and Jungner for the World Health Organization, whose criteria still guide decisions about whether to screen for a given cancer. Over subsequent decades, organized screening programs for several cancers were developed, alongside growing attention to the harms of overdiagnosis and to global inequalities in cancer burden documented by successive GLOBOCAN reports.

Debates

Balancing benefit and harm in cancer screening

Screening can reduce mortality but also produces false positives and overdiagnosis, leading to treatment of cancers that would never have caused harm; deciding when the net benefit justifies a program remains a central and contested judgement.

Key figures

• J. M. G. Wilson
• Gunnar Jungner
• Freddie Bray

Seminal works

• wilson-jungner-1968
• bray-2024

Frequently asked questions

Is detecting cancer earlier through screening always beneficial?

Not always. Screening can reduce deaths from some cancers, but it also produces false positives and can lead to overdiagnosis, so a program is only justified when the benefits clearly outweigh these harms.

What makes a cancer suitable for a screening program?

Broadly, the cancer should be an important problem with a detectable early stage, there must be an acceptable and accurate test and an effective treatment, and the overall benefits must outweigh the harms and costs.